Please login to the form below

Not currently logged in
Email:
Password:

umeclidinium bromide

This page shows the latest umeclidinium bromide news and features for those working in and with pharma, biotech and healthcare.

GSK gets maintenance indication for Trelegy

GSK gets maintenance indication for Trelegy

The new US label means Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) can be used in a broader population of chronic obstructive pulmonary disease (COPD) patients with difficulty breathing or who see ... GSK claims Trelegy has made the

Latest news

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    The EU regulator cleared Trelegy (fluticasone furoate/umeclidinium/vilanterol) - considered to be the most important new product in the company’s ailing respiratory franchise - as a maintenance treatment in adults with ... GSK has been bringing other

  • GSK files first application for triple COPD therapy GSK files first application for triple COPD therapy

    The therapy is a single device delivering inhaled corticosteroid (ICS) fluticasone furoate, long-acting beta agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium - covering the three most widely-used ... protect its

  • GSK's Bexsero vaccine growing fast, despite GSK's Bexsero vaccine growing fast, despite "tight" supply

    The product continued to slide, but newer drugs such as Anoro (vilanterol/umeclidinium bromide), Breo (vilanterol/fluticasone furoate) and new severe asthma therapy Nucala (mepolizumab) more than offset the decline, with

  • New drugs breathe life into GSK's respiratory business New drugs breathe life into GSK's respiratory business

    New asthma and COPD drugs such as Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide) added £243m ($319m) in the quarter, more than offsetting a 13% decline in Seretide

  • GSK's triple COPD therapy tops Symbicort in phase III trial GSK's triple COPD therapy tops Symbicort in phase III trial

    The phase III FULFIL trial compared the once-daily triple therapy - consisting of corticosteroid fluticasone furoate, long-acting muscarinic antagonist (LAMA) umeclidinium and long-acting beta agonist (LABA) vilanterol - to Symbicort, ... These include

More from news
Approximately 2 fully matching, plus 36 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...